Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014–2022)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014–2022) ; volume:79 ; number:9 ; day:14 ; month:7 ; year:2023 ; pages:1239-1248 ; date:9.2023
European journal of clinical pharmacology ; 79, Heft 9 (14.7.2023), 1239-1248, 9.2023
- Creator
-
Lin, Jialing
Pearson, Sallie-Anne
Greenfield, Jerry R.
Park, Kyeong Hye
Havard, Alys
Brieger, David
Day, Richard O.
Falster, Michael O.
Oliveira Costa, Juliana de
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00228-023-03539-8
- URN
-
urn:nbn:de:101:1-2023110412590023848230
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lin, Jialing
- Pearson, Sallie-Anne
- Greenfield, Jerry R.
- Park, Kyeong Hye
- Havard, Alys
- Brieger, David
- Day, Richard O.
- Falster, Michael O.
- Oliveira Costa, Juliana de
- SpringerLink (Online service)
Other Objects (12)
Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists
Knowledge gap and prescribing patterns of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors among Chinese doctors
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions : state of the art
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review
Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors
The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition?
Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists
Knowledge gap and prescribing patterns of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors among Chinese doctors
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions : state of the art
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review
Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors
The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition?
Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists
Knowledge gap and prescribing patterns of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors among Chinese doctors
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions : state of the art
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review
Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors
The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors